Cocrystal Pharma Inc reports results for the quarter ended June 30 - Earnings Summary

Cocrystal Pharma

13/08/2026 14:31

Cocrystal Pharma Inc COCP.OQ reported a quarterly adjusted loss of 23 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -20 cents.  The mean expectation of two analysts for the quarter was for a loss of 16 cents per share. Wall Street expected results to range from -18 cents to -15 cents per share.
Revenue was $105.00 thousand​; analysts expected zero. 
Cocrystal Pharma Inc's reported EPS for the quarter was a loss of 23 cents​.
The company reported a quarterly loss of $3.16 million.
Cocrystal Pharma Inc shares had risen by 6.7% this quarter and gained 14.4% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Cocrystal Pharma Inc is $9.00, about 87.6% above its last closing price of $1.12
This summary was machine generated from LSEG data August 13 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.16
-0.23
Missed
Mar. 31 2026 
-0.15
-0.17
Missed
Dec. 31 2025 
-0.17
-0.17
Met
Sep. 30 2025 
-0.21
-0.19
Beat